Literature DB >> 32070858

Infections in patients diagnosed with multiple sclerosis: A multi-database study.

R Persson1, S Lee2, M Ulcickas Yood3, Capt M Wagner Usn Mc4, N Minton2, S Niemcryk2, A Lindholm2, A M Evans5, S S Jick6.   

Abstract

BACKGROUND: Recent data on the rates of infections among patients with multiple sclerosis (MS) are sparse. The objective of this study was to quantify incidence of infections in patients with MS compared with a matched sample of patients without MS (non-MS).
METHODS: This study was conducted in two separate electronic medical databases: the United States Department of Defense (US-DOD) military health care system and the United Kingdom's Clinical Practice Research Datalink GOLD (UK-CPRD). We identified patients with a first recorded diagnosis of MS between 2001 and 2016 (UK-CPRD) or 2004 and 2017 (US-DOD) and matched non-MS patients. We identified infections recorded after the MS diagnosis date (or the matched date in non-MS patients) and calculated incidence rates (IRs) and incidence rate ratios (IRRs) with 95% confidence intervals (CIs) by infection site and type.
RESULTS: Relative to non-MS patients, MS patients had higher rates of any infection (US-DOD IRR 1.76; 95% CI 1.72-1.80 and UK-CPRD IRR 1.25; 95% CI 1.21-1.29) and a two-fold higher rate of hospitalized infections (US-DOD IRR 2.43; 95% CI 2.23-2.63 and UK-CPRD IRR 2.00; 95% CI 1.84-2.17). IRs of any infection were higher in females compared with males in both MS and non-MS patients, while IRs of hospitalized infections were similar between sexes in both MS and non-MS patients. The IR of first urinary tract or kidney infection was nearly two-fold higher in MS compared with non-MS patients (US-DOD IRR 1.88; 95% CI 1.81-1.95 and UK-CPRD IRR 1.97; 95% CI 1.86-2.09) with higher rates in females compared with males. IRs for any opportunistic infection, candidiasis and any herpes virus were increased between 20 and 52% among MS patients compared with non-MS patients. IRs of meningitis, tuberculosis, hepatitis B and C were all low.
CONCLUSION: MS patients have an increased risk of infection, notably infections of the renal tract, and a two-fold increased risk of hospitalized infections compared with non-MS patients.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology; Infections; Multiple sclerosis; Opportunistic infections

Mesh:

Year:  2020        PMID: 32070858     DOI: 10.1016/j.msard.2020.101982

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  22 in total

Review 1.  An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.

Authors:  Bulent Kantarcioglu; Omer Iqbal; Joseph Lewis; Charles A Carter; Meharvan Singh; Fabio Lievano; Mark Ligocki; Walter Jeske; Cafer Adiguzel; Grigoris T Gerotziafas; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

Review 2.  Rituximab for people with multiple sclerosis.

Authors:  Graziella Filippini; Jera Kruja; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2021-11-08

3.  COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy.

Authors:  Andrew Wolf; Enrique Alvarez
Journal:  Neurol Clin Pract       Date:  2021-08

4.  The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre.

Authors:  Matteo Lucchini; Paola Del Giacomo; Valeria De Arcangelis; Viviana Nociti; Assunta Bianco; Chiara De Fino; Giorgia Presicce; Alessandra Cicia; Vincenzo Carlomagno; Massimiliano Mirabella
Journal:  J Pers Med       Date:  2022-04-07

5.  FcγRIIb Expression Is Decreased on Naive and Marginal Zone-Like B Cells From Females With Multiple Sclerosis.

Authors:  Stephanie Trend; Jonatan Leffler; Ingrid Teige; Björn Frendéus; Allan G Kermode; Martyn A French; Prue H Hart
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

6.  Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials.

Authors:  Zhao Zhao; Chun-Lai Ma; Zhi-Chun Gu; Yue Dong; Yang Lv; Ming-Kang Zhong
Journal:  Front Immunol       Date:  2021-03-08       Impact factor: 7.561

7.  Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study.

Authors:  Nabil Seery; Sifat Sharmin; Vivien Li; Ai-Lan Nguyen; Claire Meaton; Roberts Atvars; Nicola Taylor; Kelsey Tunnell; John Carey; Mark P Marriott; Katherine A Buzzard; Izanne Roos; Chris Dwyer; Josephine Baker; Lisa Taylor; Kymble Spriggs; Trevor J Kilpatrick; Tomas Kalincik; Mastura Monif
Journal:  CNS Drugs       Date:  2021-04-13       Impact factor: 5.749

Review 8.  Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.

Authors:  Patricia K Coyle; Anne Gocke; Megan Vignos; Scott D Newsome
Journal:  Adv Ther       Date:  2021-06-01       Impact factor: 3.845

Review 9.  COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?

Authors:  Luigi Ferini-Strambi; Maria Salsone
Journal:  J Neurol       Date:  2020-07-21       Impact factor: 4.849

10.  Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.

Authors:  Carlos Guevara; Eduardo Villa; Carlos Silva Rosas; Violeta Diaz; Rodrigo Naves
Journal:  Mult Scler Relat Disord       Date:  2020-05-23       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.